Tandem Diabetes Care TNDM Acquired in-process research and development expenses
Acquired in-process research and development expenses at other companies
Other financials
Where this comes from
Reported directly by Tandem Diabetes Care in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff.
The official record: Tandem Diabetes Care’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tandem Diabetes Care's acquired in-process research and development expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tandem Diabetes Care's acquired in-process research and development expenses?
- Tandem Diabetes Care (TNDM) reported acquired in-process research and development expenses of $0 in Q1 2026.
- How has Tandem Diabetes Care's acquired in-process research and development expenses changed year-over-year?
- Tandem Diabetes Care's acquired in-process research and development expenses decreased by 100.0% year-over-year, from $75.22M to $0.
- What does acquired in-process research and development expenses mean?
- This represents the value assigned to research and development projects acquired through business combinations that have not yet reached technological feasibility. It reflects the company's strategy of inorganic innovation by purchasing external intellectual property rather than developing it entirely in-house. Investors monitor this to assess the cost and strategic focus of the company's external growth and pipeline expansion efforts.